Related Experiment Video
Updated: May 14, 2026
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Correlation between mild behavioral impairment and peripheral blood biomarkers in patients with mild cognitive
Wei Liang1,2, Lan Wang1,3, Mei Song1
1Mental Health Center, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China.
Background:
Mild behavioral impairment (MBI) refers to the neurobehavioral symptoms observed in older adults that may be potential risk factors for neurodegenerative diseases. While a significant number studies have explored the association between cerebrospinal fluid and MBI, only a few have examined the connection between plasma biomarkers and MBI.
Aim:
To examine the prevalence of MBI in healthy older adults (HOAs) and individuals with mild cognitive impairment (MCI), as well as the association between MBI and plasma biomarkers of Alzheimer's disease (AD).
Methods:
We enrolled a total of 241 subjects, which included 136 HOAs and 105 MCIs, from the Yuhua District of Shijiazhuang City, Hebei Province, China. The MBI symptom checklist (MBI-C) was utilized for the assessment and diagnosis of MBI, and a score of MBI-C ≥ 6.5 was considered indicative of the condition. Fasting venous blood samples were collected from 70 patients, 32 HOAs and 38 MCIs, and levels of amyloid β-protein (Aβ) 40, Aβ42, and hyperphosphorylated tau (p-Tau217) in these samples were measured using an enzyme-linked immunosorbent assay.
Results:
The prevalence of MBI in the HOAs and MCI groups was 4.4% and 15.3%, respectively (χ 2 = 7.262, P = 0.007), with particularly notable decreases in motivation and increases in impulse dyscontrol (the highest detection rate) and social inappropriateness (P < 0.05). The total MBI score correlated with Aβ42 and p-Tau217 (r = -0.385, P = 0.019; r = -0.330, P = 0.041), but not with Aβ40 or the Aβ42/40 ratio. Among the subdomains, impulse dyscontrol was correlated with Aβ42 (r = -0.401, P = 0.025).
Conclusion:
Both MCI and HOAs have exhibited a higher prevalence of MBI, with changes in impulse control behavior being the most common. MBI not only presents as an independent risk factor for cognitive decline but is also linked with AD-related peripheral biomarkers.
Insights
Mild behavioral impairment (MBI) is more common in older adults with mild cognitive impairment (MCI) and healthy older adults (HOAs). MBI is linked to Alzheimer's disease biomarkers, suggesting it may predict cognitive decline.
Area of Science:
- Neuroscience
- Gerontology
- Biomarker Research
Background:
- Mild behavioral impairment (MBI) encompasses neurobehavioral symptoms in older adults, potentially indicating risk for neurodegenerative diseases.
- Research on MBI has primarily focused on cerebrospinal fluid, with limited investigation into plasma biomarkers.
Purpose of the Study:
- To determine the prevalence of MBI in healthy older adults (HOAs) and individuals with mild cognitive impairment (MCI).
- To investigate the association between MBI and plasma biomarkers related to Alzheimer's disease (AD).
Main Methods:
- 241 subjects (136 HOAs, 105 MCIs) were assessed for MBI using the MBI-C checklist (score ≥ 6.5).
- Plasma levels of amyloid β-protein (Aβ) 40, Aβ42, and hyperphosphorylated tau (p-Tau217) were measured via ELISA in a subset of 70 participants.
Main Results:
- MBI prevalence was 4.4% in HOAs and 15.3% in MCIs (P=0.007).
- Common MBI symptoms included decreased motivation, increased impulse dyscontrol, and social inappropriateness.
- MBI scores correlated with Aβ42 and p-Tau217 levels (P<0.05), with impulse dyscontrol specifically linked to Aβ42.
Conclusions:
- MBI is prevalent in both MCI and HOAs, frequently manifesting as impulse control issues.
- MBI serves as an independent risk factor for cognitive decline and is associated with peripheral Alzheimer's disease biomarkers.
Related Concept Videos
01:22Photoreceptors and Visual Pathways
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:27Diabetic Retinopathy